Angiotensin receptor/neprilysin inhibition (ARNI) and sodium-glucose cotransporter-2 (SGLT2) inhibition, originally introduced for the treatment of heart failure and diabetes respectively, turned out to be renoprotective as well, possibly by affecting the renal RAS. This evidence concerns the gene SLC5A2 and heart failure.